Literature DB >> 16143691

Comparative study of enema retention and preference in ulcerative colitis.

J R Ingram1, J Rhodes, B K Evans, R G Newcombe, G A O Thomas.   

Abstract

BACKGROUND: Therapeutic enemas are often used to treat active colitis but their retention may be limited because of urgency to defecate. Some preparations may be better retained and tolerated than others because of their physical properties. AIM: To compare patient preference and retention of four therapeutic enemas, including a nicotine enema, in patients with ulcerative colitis (UC).
METHODS: Twenty four patients with active UC received the four trial enemas-corticosteroid, 5-amino salicylate (5-ASA), and nicotine liquid enemas and a corticosteroid foam, in a randomised order, taking one enema on each of four successive nights. Patients scored them 1 to 4 for ease of administration and retention, degree of abdominal bloating, and for their overall preference.
RESULTS: Fifteen patients rated nicotine their overall favourite or second favourite, compared with 14 for corticosteroid foam and 11 for 5-ASA and corticosteroid liquids, but this was not significant (p = 0.302). Overall, there was no significant difference in overnight retention. However, the nicotine enema tended to be less well retained in patients with milder urgency but a higher proportion retained it overnight with more severe urgency (p = 0.031 compared with 5-ASA enema).
CONCLUSION: There was no significant difference in patient preference or overall duration of retention for the four enemas.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16143691      PMCID: PMC1743341          DOI: 10.1136/pgmj.2004.031690

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  16 in total

1.  Treatment of ulcerative colitis with local hydrocortisone.

Authors:  S C TRUELOVE
Journal:  Br Med J       Date:  1956-12-01

2.  Treatment of ulcerative colitis with high-dose 5-aminosalicylic acid enemas.

Authors:  M Campieri; G A Lanfranchi; G Bazzocchi; C Brignola; F Sarti; G Franzin; A Battocchia; G Labo; P R Dal Monte
Journal:  Lancet       Date:  1981-08-08       Impact factor: 79.321

Review 3.  Review article: topical corticosteroids in inflammatory bowel disease.

Authors:  C J Mulder; G N Tytgat
Journal:  Aliment Pharmacol Ther       Date:  1993-04       Impact factor: 8.171

4.  Treatment of distal ulcerative colitis (proctosigmoiditis) in relapse: comparison of hydrocortisone enemas and rectal hydrocortisone foam.

Authors:  W S Ruddell; R J Dickinson; M F Dixon; A T Axon
Journal:  Gut       Date:  1980-10       Impact factor: 23.059

5.  Intra-luminal nicotine reduces smooth muscle tone and contractile activity in the distal large bowel.

Authors:  J T Green; H C McKirdy; J Rhodes; G A Thomas; B K Evans
Journal:  Eur J Gastroenterol Hepatol       Date:  1999-11       Impact factor: 2.566

6.  Nitric oxide mediates a therapeutic effect of nicotine in ulcerative colitis.

Authors:  J T Green; C Richardson; R W Marshall; J Rhodes; H C McKirdy; G A Thomas; G T Williams
Journal:  Aliment Pharmacol Ther       Date:  2000-11       Impact factor: 8.171

7.  A randomised trial comparing mesalazine and prednisolone foam enemas in patients with acute distal ulcerative colitis.

Authors:  F I Lee; D P Jewell; V Mani; M R Keighley; R D Kingston; C O Record; R H Grace; S Daniels; J Patterson; K Smith
Journal:  Gut       Date:  1996-02       Impact factor: 23.059

8.  Better quality of therapy with 5-ASA colonic foam in active ulcerative colitis. A multicenter comparative trial with 5-ASA enema.

Authors:  M Campieri; P Paoluzi; G D'Albasio; G Brunetti; A Pera; L Barbara
Journal:  Dig Dis Sci       Date:  1993-10       Impact factor: 3.199

9.  Differential effect of nitric oxide synthase inhibition on sigmoid colon longitudinal and circular muscle responses to nicotine and nerve stimulation in vitro.

Authors:  H C McKirdy; C E Richardson; J T Green; J Rhodes; G T Williams; R W Marshall
Journal:  Br J Surg       Date:  2004-02       Impact factor: 6.939

10.  5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis.

Authors:  L R Sutherland; F Martin; S Greer; M Robinson; N Greenberger; F Saibil; T Martin; J Sparr; E Prokipchuk; L Borgen
Journal:  Gastroenterology       Date:  1987-06       Impact factor: 22.682

View more
  3 in total

1.  Ibrutinib attenuated DSS-induced ulcerative colitis, oxidative stress, and the inflammatory cascade by modulating the PI3K/Akt and JNK/NF-κB pathways.

Authors:  Liangliang Hao; Lina Tariq Alkry; Abdullah Alattar; Muhammad Faheem; Reem Alshaman; Fawad Ali Shah; Shupeng Li
Journal:  Arch Med Sci       Date:  2022-04-20       Impact factor: 3.707

2.  Protective Effects of SIRT6 Overexpression against DSS-Induced Colitis in Mice.

Authors:  Kang Xu; Yannan Guo; Lu Ping; Ying Qiu; Qingfei Liu; Zhongchi Li; Zhao Wang
Journal:  Cells       Date:  2020-06-22       Impact factor: 6.600

3.  TREM-1-dependent M1 macrophage polarization restores intestinal epithelium damaged by DSS-induced colitis by activating IL-22-producing innate lymphoid cells.

Authors:  Fu-Chen Yang; Po-Yuan Chiu; Yun Chen; Tak W Mak; Nien-Jung Chen
Journal:  J Biomed Sci       Date:  2019-06-12       Impact factor: 8.410

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.